https://www.selleckchem.com/pr....oducts/conteltinib-c
Glucagon-like peptide1 (GLP-1) receptor agonists (RAs) approved to date are administered by injection; therefore, patient perceptions of an oral GLP-1 RA are unknown. This discrete choice experiment explored preferences for (unbranded) oral and injectable GLP-1 RA profiles among Japanese patients with type2 diabetes (T2D). An online survey was designed using literature review and qualitative interview findings, and administered to Japanese patients with T2D and HbA ≥ 7.0% receiving oral antiglycaemic medication (with no expe
Like
Comment
Share
